Ignite Proteomics LLC: 2025 Audited Financials Reveal Major Operational Developments, Acquisition by Aditxt, Inc.
Key Points:
- Ignite Proteomics LLC, formed in May 2024, operates a medical laboratory acquired from Theralink Technologies Inc. and provides proteomic diagnostic and research services.
- IMAC Holdings, Inc. was the sole owner throughout the periods presented, with Ignite becoming a wholly owned subsidiary of Aditxt, Inc. in March 2026.
- Financial statements show substantial losses and negative cash flows, raising doubts about the Company’s ability to continue as a going concern.
- Significant impairment loss recognized on laboratory equipment due to revenue shortfall.
- Aditxt, Inc. acquired Ignite for \$36 million in Series A-2 Convertible Preferred Stock, which could significantly impact both companies’ valuations.
Detailed Financial and Operational Highlights
Company Formation and Operations:
Ignite Proteomics LLC was founded on May 30, 2024, as a Delaware LLC. The company operates a medical laboratory acquired from Theralink Technologies Inc. and provides clinical diagnostic testing, research contracts, and participates in clinical trials. It has obtained Medicare billing credentials for its Ignite proteomics test and is pursuing additional third-party payer credentials.
Ownership Structure:
IMAC Holdings, Inc. was the sole member during the reporting periods. On March 11, 2026, Aditxt, Inc. completed the acquisition of Ignite Proteomics, making it a wholly owned subsidiary. The purchase consideration was 36,000 shares of Series A-2 Convertible Preferred Stock, with an aggregate stated value of \$36 million.
Financial Performance:
- Revenue: \$43,539 for the year ended December 31, 2025, down from \$72,050 for the period from May 30, 2024 to December 31, 2024.
- Cost of Revenue: \$402,063 in 2025, \$311,832 in 2024 period.
- Gross Loss: \$(358,524) in 2025, \$(239,782) in 2024 period.
- Operating Expenses: \$5,342,674 in 2025, \$2,000,901 in 2024 period. Notably, employee expenses accounted for \$3,768,348 in 2025 and \$1,193,173 in 2024.
- Impairment Loss: \$748,101 recognized due to revenue shortfall from laboratory equipment.
- Net Loss: \$(5,701,059) in 2025, \$(2,240,683) in 2024 period.
- Cash Position: Cash at December 31, 2025 was \$13,228, up from \$7 at December 31, 2024.
- Member’s Deficit: \$(6,807,109) at year-end 2025, compared to \$(1,106,050) at year-end 2024.
Balance Sheet Highlights:
- Total Assets: \$257,211 at December 31, 2025, down from \$1,087,068 at December 31, 2024, primarily due to impairment of laboratory equipment.
- Current Liabilities: \$7,064,320 at December 31, 2025, up from \$2,193,118 at December 31, 2024.
- Intercompany Payables: \$4,578,815 at year-end 2025, up from \$1,744,595 at year-end 2024, reflecting ongoing funding from IMAC Holdings.
Going Concern Warning:
The independent auditor’s report highlights substantial doubt about Ignite Proteomics’ ability to continue as a going concern due to recurring losses and negative cash flows from operations. No adjustments have been made to the financial statements for potential outcomes should the Company be unable to continue operations.
Impairment and Asset Valuation:
A significant impairment charge of \$748,101 was taken on laboratory equipment acquired from Theralink Technologies, triggered by a revenue shortfall and minimal cash flows. The carrying value of the equipment was written down to zero.
Related Party Transactions:
IMAC Holdings contributed medical equipment and inventory valued at \$1,043,862 and \$90,771, respectively, at inception. Ongoing funding needs have been met through intercompany payables.
Segment Reporting:
Ignite operates in a single business segment—precision medicine in cancer treatment—with all activities located in the United States.
Contingencies:
Management is not aware of any legal matters or claims likely to have a material impact on the Company’s financial condition or liquidity.
Acquisition by Aditxt, Inc.: Shareholder-Relevant News
Transaction Details:
On March 11, 2026, Aditxt, Inc. acquired 100% of Ignite Proteomics LLC’s membership interests from IMAC Holdings and other equity holders. The transaction was settled via the issuance of 36,000 shares of Series A-2 Convertible Preferred Stock, with an aggregate stated value of \$36 million. This acquisition positions Ignite as a wholly owned subsidiary of Aditxt, Inc., and may have significant implications for both companies’ share values.
Potential Price Sensitivity:
- The acquisition price and structure (\$36 million in preferred stock) could impact the valuation and capital structure of Aditxt, Inc.
- Ignite’s ongoing losses and going concern risk may affect investor sentiment toward Aditxt, especially as purchase accounting adjustments are yet to be reflected in consolidated financials.
- The impairment of laboratory assets and substantial member’s deficit signal operational risks that shareholders should monitor.
Conclusion
Ignite Proteomics LLC’s 2025 financial statements reveal a company struggling with significant losses, operational challenges, and asset impairments. The completed acquisition by Aditxt, Inc.—valued at \$36 million—marks a pivotal event for both companies, with potential implications for share values, investor confidence, and strategic direction. Investors in both Aditxt, Inc. and IMAC Holdings should closely monitor subsequent developments, including how Aditxt integrates Ignite’s operations and addresses its going concern risks.
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. The information herein is based on publicly available audited financial statements and may be subject to change or updates.
View Aditxt, Inc. Historical chart here
